A one-year study comparing the efficacy and safety of rosiglitazone and glibenclamide in the treatment of type 2 diabetes.

@article{Hanefeld2007AOS,
  title={A one-year study comparing the efficacy and safety of rosiglitazone and glibenclamide in the treatment of type 2 diabetes.},
  author={Markolf Hanefeld and Rita Patwardhan and Nigel P. Jones},
  journal={Nutrition, metabolism, and cardiovascular diseases : NMCD},
  year={2007},
  volume={17 1},
  pages={13-23}
}
BACKGROUND AND AIM This study was designed to compare the efficacy of rosiglitazone and glibenclamide in individuals with type 2 diabetes over a 12-month period. METHODS AND RESULTS A total of 598 patients were randomized to double-blind treatment for 52 weeks with rosiglitazone 4 mg/d (n=200), rosiglitazone 8 mg/d (n=191) or glibenclamide (n=207; dose adjusted up to 15 mg/d over the first 12 weeks according to clinical response). Changes in fasting plasma glucose (FPG), haemoglobin A1c… CONTINUE READING